Sai Life Sciences Reports 12% Revenue Growth in Q1 FY27, Highlights CRO and CDMO Strength

Sai Life Sciences Reports 12% Revenue Growth in Q1 FY27, Highlights CRO and CDMO Strength​

Sai Life Sciences Limited released its Investor Presentation for the quarter ended June 30, 2026, highlighting continued progress across both its Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) businesses. The company reported a revenue of ₹ 554 crore in Q1 FY27, representing a 12% increase year-on-year.

The management emphasized the evolving landscape of pharmaceutical outsourcing, noting that large pharmaceutical companies now seek partners who offer integrated discovery and development programs rather than simply executing individual pieces of work. Mr. Krishna Kanumuri, MD & CEO, stated that the company's combination of technology base, scientific talent, and culture is key to securing significant engagements from large pharma clients, ensuring a healthy and sustained pipeline over multiple years.

Mr. Siva Chittor, Whole-time Director & CFO, noted that strong momentum was maintained in the CRO segment, which grew by 24% year-on-year. In terms of CDMO operations, the CMC pipeline remains robust, featuring 33 active commercial molecules and 14 late-phase molecules.

Operational Excellence and Key Achievements​

The company reported significant operational milestones beyond financial performance. Sai Life Sciences achieved EcoVadis Platinum Rating 2026, placing it among the top 1% of companies globally assessed for sustainability performance. Furthermore, the company operationalized a new 100,000 sq. ft. R&D facility at Genome Valley in Hyderabad and successfully executed commercial-scale Photo Flow Chemistry for a late-phase innovator program.

The High-Throughput Experimentation (HTE) platform has been commissioned at the Hyderabad R&D campus to facilitate faster route scouting, process optimization, and scale-up decisions. Strategic priorities moving forward include establishing an integrated peptide platform spanning discovery to manufacturing, adding a Drug Product facility to complement API development, and building a future-ready scientific organization.

Financial Snapshot and Business Composition​

The company maintains confidence in executing its long-term growth strategy, with revenue growth guidance set at 15–20% and EBITDA projected within the 28–30% range. The CRO segment accounts for 40% of the revenue mix.

Key insights from the Q1 FY27 snapshot are detailed below:


The consolidated financial highlights for the quarter are presented in the table below:

Client Reach and Industry Position​

Sai Life Sciences, founded in 1999, operates as an integrated CRDMO (Contract Research, Development, and Manufacturing Organization). The company is trusted by over 300 global clients, including 19 of the top 25 global pharmaceutical companies across the US, UK, EU, and Japan.

The firm boasts a 26% Compound Annual Growth Rate (CAGR) in revenue over the last five years. Key operational strengths include its commitment to digitalization, which has progressed from converting data and documents to digital formats (since 2017) to leveraging AI/ML models for manufacturing process prediction. The company also places high importance on quality assurance and sustainability, reporting zero liquid discharge and holding a carbon roadmap approved by SBTi.

SAILIFE Stock Price Movement​

As of 2:30 PM, shares of Sai Life Sciences Limited are slipping by 2.45% in live trading, currently valued at ₹1378.9 after shedding ₹34.60 from the previous close. The stock trades on a volume of 681,786 shares, continuing to move downward during market hours.